BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17348459)

  • 1. Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity.
    Kobayashi R; Yoshimatsu K; Yokomizo H; Katsube T; Ogawa K
    Anticancer Res; 2007; 27(1B):675-9. PubMed ID: 17348459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer.
    Yoshimatsu K; Kuhara K; Itagaki H; Aizawa M; Yokomizo H; Fujimoto T; Otani T; Osawa G; Kobayashi R; Ogawa K
    Anticancer Res; 2008; 28(1B):373-8. PubMed ID: 18383872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
    Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
    Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress in chemotherapy for colorectal cancer].
    Sasaki T; Maeda Y
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2185-92. PubMed ID: 11142161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
    Goto A
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):896-900. PubMed ID: 16835475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line chemotherapy with low-dose leucovorin plus 5-fluorouracil (LV/5-FU) for elderly patients with metastatic colorectal cancer.
    Yoshimatsu K; Yokomizo H; Fujimoto T; Umehara A; Otani T; Matsumoto A; Osawa G; Shiozawa S; Katsube T; Naritaka Y; Ogawa K
    Anticancer Res; 2007; 27(3B):1641-4. PubMed ID: 17595789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer.
    Yoshimatsu K; Yokomizo H; Fujimoto T; Umehara A; Otani T; Matsumoto A; Osawa G; Ogawa K
    Anticancer Res; 2007; 27(3B):1657-61. PubMed ID: 17595792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Host immunity in colorectal cancer patients treated with low-dose Leucovorin plus 5-fluorouracil].
    Kobayashi R; Yoshimatsu K; Ishibashi K; Yokomizo H; Umehara A; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1783-5. PubMed ID: 15553714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
    Tokunaga Y; Sasaki H; Matsueda S
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1127-31. PubMed ID: 21772096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
    Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
    Matsukura S; Samejima R; Tanaka M; Hidaka K
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):893-6. PubMed ID: 15222107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Controversy of treatment for advanced colorectal cancer--intermedisine].
    Sato A; Shimada K; Taguchi S
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1260-9. PubMed ID: 14518404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
    Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
    Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
    J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
    Tsavaris N; Kosmas C; Skopelitis H; Papadoniou N; Polyzos A; Zografos G; Adoniou E; Gryniatsos J; Felekouras E; Zacharakis M; Sigala F; Bacoyiannis C; Papastratis G; Papalambros E
    Chemotherapy; 2007; 53(4):282-91. PubMed ID: 17496414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    Saltz LB; Niedzwiecki D; Hollis D; Goldberg RM; Hantel A; Thomas JP; Fields AL; Mayer RJ
    J Clin Oncol; 2007 Aug; 25(23):3456-61. PubMed ID: 17687149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
    Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
    Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
    Ito T; Hata Y; Matsuoka S; Nakajima N; Yokoyama R; Honda S; Sano F; Akasaka Y; Ohmori K
    Gan To Kagaku Ryoho; 2005 Sep; 32(9):1289-93. PubMed ID: 16184926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.